141 related articles for article (PubMed ID: 19914539)
21. Prognostic applications of gene expression signatures in breast cancer.
Normanno N; De Luca A; Carotenuto P; Lamura L; Oliva I; D'Alessio A
Oncology; 2009; 77 Suppl 1():2-8. PubMed ID: 20130425
[TBL] [Abstract][Full Text] [Related]
22. Commercialized multigene predictors of clinical outcome for breast cancer.
Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
[TBL] [Abstract][Full Text] [Related]
23. Molecular classification of breast cancer: limitations and potential.
Pusztai L; Mazouni C; Anderson K; Wu Y; Symmans WF
Oncologist; 2006 Sep; 11(8):868-77. PubMed ID: 16951390
[TBL] [Abstract][Full Text] [Related]
24. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
Gentilini O; Masullo M; Rotmensz N; Peccatori F; Mazzarol G; Smeets A; Simsek S; De Dosso S; Veronesi P; Intra M; Zurrida S; Viale G; Goldhirsch A; Veronesi U
Eur J Surg Oncol; 2005 Apr; 31(3):232-6. PubMed ID: 15780556
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
27. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
28. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
[TBL] [Abstract][Full Text] [Related]
29. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
30. Cancer is heterogeneous.
Guinebretiere JM
J Clin Oncol; 2009 Jun; 27(16):2732; author reply 2734-5. PubMed ID: 19380436
[No Abstract] [Full Text] [Related]
31. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Diaz LK; Cryns VL; Symmans WF; Sneige N
Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
33. Molecular profiling of non-small cell lung cancer: of what value in clinical practice?
Newnham GM; Thomas DM; McLachlan SA; Wright G; Conron M
Heart Lung Circ; 2008 Dec; 17(6):451-62. PubMed ID: 18676201
[TBL] [Abstract][Full Text] [Related]
34. Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?
Arnould L; Coudert B; Fumoleau P
J Clin Oncol; 2009 Jun; 27(16):2733; author reply 2734-5. PubMed ID: 19380432
[No Abstract] [Full Text] [Related]
35. Breast cancer gene microarrays pass muster.
Twombly R
J Natl Cancer Inst; 2006 Oct; 98(20):1438-40. PubMed ID: 17047189
[No Abstract] [Full Text] [Related]
36. [Biological features of breast cancer in patients under 35].
Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling in breast cancer.
Morris SR; Carey LA
Curr Opin Oncol; 2007 Nov; 19(6):547-51. PubMed ID: 17906450
[TBL] [Abstract][Full Text] [Related]
38. Clinical application of gene expression profiling in breast cancer.
Sparano JA; Fazzari M; Kenny PA
Surg Oncol Clin N Am; 2010 Jul; 19(3):581-606. PubMed ID: 20620929
[TBL] [Abstract][Full Text] [Related]
39. Predicting endocrine responsiveness: novel biomarkers on the horizon.
Kerstann KF; Bouzyk M; Abramovitz M; Leyland-Jones B
Oncology (Williston Park); 2009 Feb; 23(2):154, 156, 159. PubMed ID: 19323296
[No Abstract] [Full Text] [Related]
40. Gene profiling assay and application: the predictive role in primary therapy.
Fumagalli D; Desmedt C; Ignatiadis M; Loi S; Piccart M; Sotiriou C
J Natl Cancer Inst Monogr; 2011; 2011(43):124-7. PubMed ID: 22043058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
